Go Pro
→ The SEC Just Opened The Floodgates… (From StocksToTrade) (Ad)tc pixel Free BPTSY Stock Alerts

Biophytis (BPTSY) Competitors

$0.25 0.00 (0.00%)
As of 10/1/2026
Compare

BPTSY vs. CANF, NXTS, ITRM, NKGN, and ASLN

Should you buy Biophytis stock or one of its competitors? Biophytis's main competitors and comparable companies include Can-Fite BioPharma (CANF), Nexentis Technologies (NXTS), Iterum Therapeutics (ITRM), NKGen Biotech (NKGN), and ASLAN Pharmaceuticals (ASLN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Biophytis compare to Can-Fite BioPharma?

Can-Fite BioPharma (NYSE:CANF) and Biophytis (NASDAQ:BPTSY) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

Can-Fite BioPharma has higher revenue and earnings than Biophytis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Can-Fite BioPharma$405K5.81-$7.63M-$22.80N/A
BiophytisN/AN/A-$18.43MN/AN/A

In the previous week, Can-Fite BioPharma had 6 more articles in the media than Biophytis. MarketBeat recorded 6 mentions for Can-Fite BioPharma and 0 mentions for Biophytis. Biophytis' average media sentiment score of 0.00 beat Can-Fite BioPharma's score of -0.83 indicating that Biophytis is being referred to more favorably in the news media.

Company Overall Sentiment
Can-Fite BioPharma Negative
Biophytis Neutral

21.0% of Can-Fite BioPharma shares are held by institutional investors. Comparatively, 0.1% of Biophytis shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by company insiders. Comparatively, 3.7% of Biophytis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Can-Fite BioPharma currently has a consensus price target of $44.00, indicating a potential upside of 1,899.09%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, research analysts plainly believe Can-Fite BioPharma is more favorable than Biophytis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Can-Fite BioPharma
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Biophytis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Company Net Margins Return on Equity Return on Assets
Can-Fite BioPharmaN/A N/A N/A
Biophytis N/A N/A N/A

Can-Fite BioPharma has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, suggesting that its stock price is 146% more volatile than the broader market.

Summary

Can-Fite BioPharma beats Biophytis on 7 of the 10 factors compared between the two stocks.

How does Biophytis compare to Nexentis Technologies?

Biophytis (NASDAQ:BPTSY) and Nexentis Technologies (NASDAQ:NXTS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

Biophytis has a beta of 2.46, suggesting that its share price is 146% more volatile than the broader market. Comparatively, Nexentis Technologies has a beta of 1.85, suggesting that its share price is 85% more volatile than the broader market.

Biophytis' return on equity of 0.00% beat Nexentis Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
BiophytisN/A N/A N/A
Nexentis Technologies N/A -304.79%-178.91%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biophytis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Nexentis Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiophytisN/AN/A-$18.43MN/AN/A
Nexentis TechnologiesN/AN/A-$4M-$96.07N/A

In the previous week, Nexentis Technologies had 2 more articles in the media than Biophytis. MarketBeat recorded 2 mentions for Nexentis Technologies and 0 mentions for Biophytis. Nexentis Technologies' average media sentiment score of 0.21 beat Biophytis' score of 0.00 indicating that Nexentis Technologies is being referred to more favorably in the news media.

Company Overall Sentiment
Biophytis Neutral
Nexentis Technologies Neutral

0.1% of Biophytis shares are owned by institutional investors. Comparatively, 61.2% of Nexentis Technologies shares are owned by institutional investors. 3.7% of Biophytis shares are owned by insiders. Comparatively, 6.5% of Nexentis Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Nexentis Technologies beats Biophytis on 6 of the 9 factors compared between the two stocks.

How does Biophytis compare to Iterum Therapeutics?

Iterum Therapeutics (NASDAQ:ITRM) and Biophytis (NASDAQ:BPTSY) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
Iterum TherapeuticsN/A N/A -65.54%
Biophytis N/A N/A N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Iterum Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Biophytis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Iterum Therapeutics' average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.

Company Overall Sentiment
Iterum Therapeutics Neutral
Biophytis Neutral

Biophytis has lower revenue, but higher earnings than Iterum Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Iterum Therapeutics$390K4.10-$24.77M-$0.75N/A
BiophytisN/AN/A-$18.43MN/AN/A

Iterum Therapeutics has a beta of 2.96, indicating that its share price is 196% more volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, indicating that its share price is 146% more volatile than the broader market.

9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 0.1% of Biophytis shares are owned by institutional investors. 2.0% of Iterum Therapeutics shares are owned by company insiders. Comparatively, 3.7% of Biophytis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Iterum Therapeutics beats Biophytis on 4 of the 7 factors compared between the two stocks.

How does Biophytis compare to NKGen Biotech?

NKGen Biotech (NYSE:NKGN) and Biophytis (NASDAQ:BPTSY) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

In the previous week, NKGen Biotech's average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.

Company Overall Sentiment
NKGen Biotech Neutral
Biophytis Neutral

NKGen Biotech has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, indicating that its share price is 146% more volatile than the broader market.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NKGen BiotechN/AN/A-$82.94M-$1.68N/A
BiophytisN/AN/A-$18.43MN/AN/A

Company Net Margins Return on Equity Return on Assets
NKGen BiotechN/A N/A -479.36%
Biophytis N/A N/A N/A

76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 0.1% of Biophytis shares are owned by institutional investors. 10.4% of NKGen Biotech shares are owned by company insiders. Comparatively, 3.7% of Biophytis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Biophytis beats NKGen Biotech on 3 of the 5 factors compared between the two stocks.

How does Biophytis compare to ASLAN Pharmaceuticals?

Biophytis (NASDAQ:BPTSY) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

0.1% of Biophytis shares are held by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. 3.7% of Biophytis shares are held by insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Biophytis has a beta of 2.46, indicating that its stock price is 146% more volatile than the broader market. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

In the previous week, Biophytis' average media sentiment score of 0.00 equaled ASLAN Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Biophytis Neutral
ASLAN Pharmaceuticals Neutral

Biophytis has higher earnings, but lower revenue than ASLAN Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiophytisN/AN/A-$18.43MN/AN/A
ASLAN Pharmaceuticals$12M0.10-$44.22M-$21.92N/A

Biophytis' return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
BiophytisN/A N/A N/A
ASLAN Pharmaceuticals N/A -8,454.87%-121.60%

Summary

Biophytis beats ASLAN Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Get Biophytis News Delivered to You Automatically

Sign up to receive the latest news and ratings for BPTSY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BPTSY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BPTSY vs. The Competition

Export
MetricBiophytisPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$586K$12.26B$7.13B$13.27B
Dividend YieldN/A2.63%2.53%15.88%
P/E RatioN/A797.17273.9926.15
Price / SalesN/A751.40608.6593.06
Price / CashN/A81.7977.3851.25
Price / Book-0.0210.3810.886.34
Net Income-$18.43M$2.84B$3.50B$361.18M
7 Day PerformanceN/A-1.27%-1.62%-1.17%
1 Month PerformanceN/A-5.49%-5.90%-3.40%
1 Year PerformanceN/A-3.38%9.47%3.28%

Biophytis Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BPTSY
Biophytis
N/A$0.25
flat		N/AN/A$586KN/AN/A30
CANF
Can-Fite BioPharma
1.9476 of 5 stars		$2.16
-3.1%		$44.00
+1,937.0%		-82.0%$2.31M$405KN/A5
NXTS
Nexentis Technologies
1.047 of 5 stars		$1.46
+3.2%		N/A-94.7%$2.11M$210KN/A9
ITRM
Iterum Therapeutics
0.0254 of 5 stars		$0.03
flat		N/AN/A$1.60M$390KN/A10
NKGN
NKGen Biotech
N/A$0.01
flat		N/A-89.1%$1.57MN/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BPTSY) was last updated on 10/2/2026 by MarketBeat.com Staff.
From Our Partners
This AI fund posted a 34 percent annualized payout last month
One small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...
Investors Alley | Sponsoredtc pixel
Elon Warns "America Will Go Bankrupt". Trump's Plan Inside.
National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...
American Hartford Gold | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The SEC Just Opened The Floodgates…
The SEC removed the 25 year old Pattern Day Trader rule in June 2026, cutting the minimum to open a trading ac...
StocksToTrade | Sponsoredtc pixel
The end of AI data centers coming?
Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...
Chaikin Analytics | Sponsoredtc pixel
Major Buy Alert Issued for October 31st
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
The "velvet rope" stock setups hiding from regular indicators
K.I.R.A. is a new trading engine built to flag market setups before they show up on standard charts. Former...
The TradingPub | Sponsoredtc pixel